AUPM959894A0 - Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4 - Google Patents

Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4

Info

Publication number
AUPM959894A0
AUPM959894A0 AUPM9598A AUPM959894A AUPM959894A0 AU PM959894 A0 AUPM959894 A0 AU PM959894A0 AU PM9598 A AUPM9598 A AU PM9598A AU PM959894 A AUPM959894 A AU PM959894A AU PM959894 A0 AUPM959894 A0 AU PM959894A0
Authority
AU
Australia
Prior art keywords
fusion proteins
activity against
cytotoxic activity
cells overexpressing
against cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPM9598A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRC for Biopharmaceutical Research Pty Ltd
Original Assignee
CRC for Biopharmaceutical Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRC for Biopharmaceutical Research Pty Ltd filed Critical CRC for Biopharmaceutical Research Pty Ltd
Priority to AUPM9598A priority Critical patent/AUPM959894A0/en
Publication of AUPM959894A0 publication Critical patent/AUPM959894A0/en
Priority to PCT/AU1995/000767 priority patent/WO1996016176A1/en
Priority to EP95937728A priority patent/EP0804596A4/en
Priority to AU38647/95A priority patent/AU689971B2/en
Priority to JP8516384A priority patent/JPH10509949A/ja
Priority to CA002205807A priority patent/CA2205807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AUPM9598A 1994-11-22 1994-11-22 Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4 Abandoned AUPM959894A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AUPM9598A AUPM959894A0 (en) 1994-11-22 1994-11-22 Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
PCT/AU1995/000767 WO1996016176A1 (en) 1994-11-22 1995-11-17 FUSION PROTEINS WITH CYTOTOXIC ACTIVITY AGAINST CELLS OVEREXPRESSING erbB3 AND/OR erbB4
EP95937728A EP0804596A4 (en) 1994-11-22 1995-11-17 FUSED PROTEINS HAVING CYTOTOXIC ACTIVITY AGAINST ERBB3 AND / OR erBB4 OVEREXPRESSION CELLS
AU38647/95A AU689971B2 (en) 1994-11-22 1995-11-17 Fusion proteins with cytotoxic activity against cells overexpressing erbB2-4
JP8516384A JPH10509949A (ja) 1994-11-22 1995-11-17 ｅｒｂＢ２−４を過剰発現する細胞に向けられた細胞毒性活性を備えた融合タンパク質
CA002205807A CA2205807A1 (en) 1994-11-22 1995-11-17 Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM9598A AUPM959894A0 (en) 1994-11-22 1994-11-22 Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4

Publications (1)

Publication Number Publication Date
AUPM959894A0 true AUPM959894A0 (en) 1994-12-15

Family

ID=3784109

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPM9598A Abandoned AUPM959894A0 (en) 1994-11-22 1994-11-22 Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4

Country Status (5)

Country Link
EP (1) EP0804596A4 (ja)
JP (1) JPH10509949A (ja)
AU (1) AUPM959894A0 (ja)
CA (1) CA2205807A1 (ja)
WO (1) WO1996016176A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1063185C (zh) * 1996-07-04 2001-03-14 尹光环 荷瑞因子偶联物、其制备方法、含有它的组合物和应用
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
AU2003217601A1 (en) * 2002-02-21 2003-09-09 The Regents Of The University Of California A novel protein for inhibiting tumor progression and increasing nerve regeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2085329T3 (es) * 1989-02-17 1996-06-01 Merck & Co Inc Agente anticanceroso proteico.
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase

Also Published As

Publication number Publication date
CA2205807A1 (en) 1996-05-30
EP0804596A1 (en) 1997-11-05
EP0804596A4 (en) 2000-03-08
JPH10509949A (ja) 1998-09-29
WO1996016176A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
AU9482098A (en) Fusion protein systems
AU4382193A (en) BPI-immunoglobulin fusion proteins
AU3827695A (en) Antigen-binding fusion proteins
AU6208098A (en) Protein with phospholipase activity
GB9718609D0 (en) Fusion protein
AU3562299A (en) Inhibin-hbc fusion protein
AU6255096A (en) Pegylated modified proteins
AU5065198A (en) Fusion proteins having increased half-lives
AU3904399A (en) Automated storage system
EP0852627A4 (en) CELL DEATH PROTEIN
AU6138594A (en) Electrochemical fulleren system
AU8947791A (en) Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
AU6873596A (en) Allergen-xcd32 fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
AU7684896A (en) Fas ligand fusion protein
AU3823795A (en) Novel mammalian protein associated with uncontrolled cell division
AU4030697A (en) Proteins having telomerase activity
AU6979287A (en) Fusion proteins
AU1526897A (en) Fusion proteins comprising cell cycle regulatory proteins
AU2660400A (en) Rantes-derived peptides with anti-hiv activity
AU1373395A (en) Vpr receptor protein
AU7107798A (en) Hyperthermostable alpha-amylase
AU3923395A (en) Order-picking cell
AU2497095A (en) Expression systems utilizing autolyzing fusion proteins and a novel reducing polypeptide
AUPM959894A0 (en) Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4